Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| moderate |
LUCENTIS 10 mg/mL, solution for injection provides a moderate improvement in actual benefit (level III) in terms of efficacy in comparison with VISUDYNE in the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia. |
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
xqwkVWuXLk4zpVjT
Listen
